Is TDOC a Buy? What to Consider in 2026
Short answer
The bull case for Teladoc Health (TDOC) rests on Integrated Care and chronic-condition management: Integrated Care is Teladoc's enterprise backbone, bundling general medical visits, mental-health access, and chronic-care programs for diabetes and hypertension carried over from Livongo. Revenue (FY2025) is ~$2,530 million, down ~2% from ~$2,570 million in 2024. If you believe that thesis holds, the real questions become position sizing and overlap, not timing. The main risk to that view: Revenue has been roughly flat to declining for several years, and total revenue fell about ~2% in 2025, so the turnaround is about stabilization rather than growth. Whether TDOC is a buy comes down to whether you believe the thesis. This is informational, not a recommendation, and Walnut is not an investment adviser.
Teladoc Health makes money through two reporting segments. Integrated Care sells virtual-care services (general medical, chronic-condition management for diabetes and hypertension via the former Livongo programs, expert medical opinions, and licensable platform tools) mostly to employers, health plans, and hospitals on a per-member-per-month and visit-fee basis; in 2025 it was the larger and more profitable engine, with Q1 2026 revenue of about ~$395 million and a roughly ~14% adjusted EBITDA margin. BetterHelp is a direct-to-consumer online mental-health and therapy subscription brand whose paying-member count and revenue have been falling; BetterHelp revenue declined about ~9% to roughly ~$950 million in 2025 and its segment adjusted EBITDA fell about ~46% to roughly ~$42 million as marketing costs rose, prompting a pivot toward insurance-reimbursed therapy. Teladoc's history explains much of the stock's trajectory. It went public in 2015 and became the dominant US telehealth name, then in October 2020 acquired chronic-care company Livongo in a deal valued at roughly ~$18.5 billion at the peak of the pandemic-era digital-health boom. As telehealth demand normalized and Livongo enrollment underwhelmed, Teladoc wrote down the acquisition with non-cash goodwill impairment charges totaling about ~$13.4 billion in 2022, driving a historic net loss of roughly ~$13.7 billion that year. The shares fell more than 90% from their 2021 highs, and the company has since refocused on cost discipline, segment profitability, and free cash flow.
What's the case for buying TDOC?
Integrated Care and chronic-condition management
Integrated Care is Teladoc's enterprise backbone, bundling general medical visits, mental-health access, and chronic-care programs for diabetes and hypertension carried over from Livongo. It grew modestly (about ~2% in Q1 2026 to roughly ~$395 million) and carries the company's healthier margins. Continued cross-selling of chronic-care and whole-person programs into existing employer and health-plan clients is the most-cited path to stabilizing total revenue.
Free cash flow and balance-sheet discipline
Management has reoriented the company around adjusted EBITDA and free cash flow rather than top-line growth. Full-year 2025 adjusted EBITDA landed in the roughly ~$270 to ~$287 million guidance range, and 2026 guidance points to free cash flow of about ~$130 to ~$170 million. Sustained cash generation is what supports debt paydown and gives the turnaround room to play out.
BetterHelp's shift toward insurance
BetterHelp's pure direct-to-consumer model has been squeezed by higher customer-acquisition costs and falling paying users. Teladoc is moving BetterHelp toward insurance-reimbursed therapy, guiding to roughly ~$90 to ~$105 million of BetterHelp insurance revenue in 2026 with a Q4 exit run-rate of at least about ~$125 million. Whether that channel can offset the consumer decline is a central open question.
AI and scale in virtual care
As the first and largest US telehealth platform, Teladoc has scale in clinician network, data, and employer relationships, and it markets AI and analytics tools for triage, documentation, and care navigation. Embedding AI to lower the cost per visit and improve outcomes is a stated lever, though it is early and competitors are pursuing similar automation.
What are the risks to TDOC?
Revenue has been roughly flat to declining for several years, and total revenue fell about ~2% in 2025, so the turnaround is about stabilization rather than growth. BetterHelp faces intense competition for therapy customers and rising acquisition costs that have compressed its profitability, and the insurance pivot is unproven at scale. Teladoc still reports GAAP net losses (a net loss of roughly ~$64 million in Q1 2026) and carries debt, so the equity depends on cash flow and margin execution. Telehealth is crowded, with enterprise rivals, consumer-subscription players, and health plans building their own virtual care.
How is TDOC valued? (as of 2026-06)
- Revenue (FY2025): ~$2,530 million, down ~2% from ~$2,570 million in 2024
- Segment mix: Integrated Care ~$1,580 million; BetterHelp ~$950 million (FY2025)
- Adjusted EBITDA (FY2025): roughly ~$270 to ~$287 million (within guidance)
- Free cash flow: FY2025 outlook ~$170 to ~$185 million; FY2026 guidance ~$130 to ~$170 million
- Q1 2026 results: revenue ~$613.8 million (down ~2%); net loss ~$63.8 million; adjusted EBITDA ~$58.2 million
- Market cap: roughly ~$1.4 billion at a share price near ~$8 (52-week range ~$4.40 to ~$9.77)
Teladoc is now valued at a fraction of its 2021 peak, reflecting years of flat-to-declining revenue and the Livongo writedowns rather than a growth multiple. With GAAP losses ongoing, investors tend to focus on adjusted EBITDA and free cash flow as the practical yardsticks. All figures are approximate and tied to the asOf date; check the latest filings for current numbers.
How do you decide if TDOC is a buy?
Rather than asking whether TDOC is a buy in the abstract, it tends to help to answer four questions:
- Thesis: do you believe the case above, and is it still true today?
- Time horizon: a single stock can be volatile, so a longer horizon absorbs more of the swings.
- Position sizing: a thesis can be right and the sizing still wrong; decide how much of your portfolio one name should be.
- Overlap: check whether you already hold TDOC indirectly through an index or sector ETF before adding more.
For the full picture, see the TDOC stock guide (what the company does, the ETFs that hold it, similar stocks, and the themes it fits). In Walnut you can ask its AI about TDOC against your real portfolio and see your actual exposure before deciding.
The bottom line on TDOC
The bottom line: Teladoc Health's story right now is Integrated Care and chronic-condition management, with revenue (fy2025) at ~$2,530 million, down ~2% from ~$2,570 million in 2024. If you believe that narrative continues, the call is about sizing TDOC sensibly and checking overlap with what you own; if you doubt it (the risk: revenue has been roughly flat to declining for several years, and total revenue fell about ~2% in 2025, so the turnaround is about stabilization rather than growth.), it is not for you. Decide from the thesis, not the ticker. Walnut is not an investment adviser.
Build a basket around TDOC with Walnut
Use Teladoc Health as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.
FAQ
Is TDOC a good stock to buy right now?
+
The case for Teladoc Health right now is Integrated Care and chronic-condition management, with revenue (fy2025) at ~$2,530 million, down ~2% from ~$2,570 million in 2024. If you believe that thesis holds, TDOC is a way to own it and the real questions are sizing and overlap, not timing; the main risk to that view is revenue has been roughly flat to declining for several years, and total revenue fell about ~2% in 2025, so the turnaround is about stabilization rather than growth. So it comes down to whether you believe the thesis. Walnut is not an investment adviser and this is not a recommendation.
What does Teladoc Health do?
+
Teladoc Health makes money through two reporting segments.
What are the main risks of TDOC?
+
Revenue has been roughly flat to declining for several years, and total revenue fell about ~2% in 2025, so the turnaround is about stabilization rather than growth. BetterHelp faces intense competition for therapy customers and rising acquisition costs that have compressed its profitability, and the insurance pivot is unproven at scale. Teladoc still reports GAAP net losses (a net loss of roughly ~$64 million in Q1 2026) and carries debt, so the equity depends on cash flow and margin execution. Telehealth is crowded, with enterprise rivals, consumer-subscription players, and health plans building their own virtual care.
What does Teladoc do?
+
Teladoc Health is the largest US virtual-care company. It provides telehealth visits, chronic-condition management for diabetes and hypertension, expert medical opinions, and licensable platform tools through its Integrated Care segment, sold mainly to employers and health plans, and it owns BetterHelp, a direct-to-consumer online therapy and mental-health subscription brand.
Why did Teladoc stock crash?
+
Teladoc surged during the pandemic, then fell more than 90% from its 2021 highs as telehealth demand normalized. The biggest blow was its roughly ~$18.5 billion Livongo acquisition, which it wrote down with about ~$13.4 billion of non-cash goodwill impairments in 2022, producing a historic net loss near ~$13.7 billion. Slowing growth compounded the decline.
Is TDOC a good stock to buy right now?
+
That depends on your goals, time horizon, and risk tolerance, and this is not advice. The bull case is a cash-generative turnaround at a low valuation with a recovering BetterHelp insurance channel. The bear case is years of flat-to-declining revenue, no GAAP profit, and stiff competition. Reasonable investors weigh both differently.
Does TDOC pay a dividend?
+
No. Teladoc Health does not pay a dividend. As a company still reporting GAAP net losses and focused on rebuilding free cash flow and paying down debt, it directs cash toward operations and its balance sheet rather than shareholder distributions. Any return from the stock would come from price changes, not income.
Walnut is informational and is not an investment adviser. This page is educational and not a recommendation to buy or sell TDOC; figures are approximate and dated, and your own situation, time horizon, and risk tolerance should drive any decision. Verify current data before investing.